The study vaccine has been developed for use in pre-dialysis/ haemodialysis patients and immuno-compromised individuals who could have or had a sub-optimal response following vaccination for hepatitis B with currently available commercial vaccines (target population). This study will aim to confirm in a clinical setting the consistency of production of three lots of the vaccine.

Double-blind, randomised, single centre study with three groups receiving three different lots of Henogen's adjuvanted hepatitis B vaccine according to 0, 1 months schedule. Blood samples will be taken at Month 0, Months 1 and 2.

Inclusion Criteria:

• A healthy male or female adult aged between 18 and 40 years.
• Written informed consent obtained from the subject

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
• Administration of a vaccine not foreseen by the study protocol within 14 days (killed vaccine) or 30 days (attenuated/ live vaccine) before the first vaccine dose.
• Concurrently participating in another clinical study or exposure to an investigational or a non-investigational product (pharmaceutical product or device).
• History of hepatitis B infection.
• Known exposure to hepatitis B virus within 6 months.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
• Pregnant or lactating female.
• Female planning to become pregnant or planning to discontinue contraceptive precautions.